Study of Fas (CD95) and FasL (CD178) polymorphisms in liver transplant recipients.
The Fas receptor is capable of transducing apoptotic cell death upon interaction with their ligand (FasL). Recent studies suggest that the Fas/FasL system is involved both in graft rejection and in transplantation tolerance. In this study, we analyzed the effect of Fas and FasL polymorphisms in liver allograft outcome. Fas and FasL polymorphisms were analyzed in 151 primary liver graft recipients. The Fas (-670 A/G) and the FasL (IVS2nt -124 A/G and IVS3nt 169 T/delT) polymorphisms were analyzed by polymerase chain reaction-restriction fragment length polymorphism. Fas -1377 G/A polymorphism was determined by allele-specific amplification. Fas and FasL polymorphisms were not associated with acute and chronic rejection in liver transplant. In contrast, those recipients bearing the AA -670 Fas genotype showed significantly lower graft survival rate (S = 40%) than those bearing the GA genotype (S = 63.1%). These differences were detected from the first year post-transplant. Multivariate analysis confirmed that the AA genotype increased the risk of liver graft loss. This work suggests for the first time a possible harmful effect of Fas -670 AA genotype on liver graft survival, whereas the Fas and FasL polymorphisms are not associated with acute or chronic rejection in liver graft recipients.
Marín
L A
LA
Immunology Service, University Hospital Virgen de la Arrixaca, Murcia, Spain. lmarin24@ono.com
Muro
M
M
Moya-Quiles
M R
MR
Miras
M
M
Minguela
A
A
Bermejo
J
J
Sanchez-Bueno
F
F
Parrilla
P
P
Alvarez-López
M R
MR
D000328:Adult; D000943:Antigens, Differentiation; D015331:Cohort Studies; D018450:Disease Progression; D053222:Fas Ligand Protein; D005260:Female; D020022:Genetic Predisposition to Disease; D006084:Graft Rejection / Q000235:genetics; D006085:Graft Survival / Q000235:genetics; D006801:Humans; D016031:Liver Transplantation; D008297:Male; D008562:Membrane Glycoproteins / Q000235:genetics*; D008875:Middle Aged; D015999:Multivariate Analysis; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D013997:Time Factors; D048069:Tumor Necrosis Factors / Q000235:genetics*; D019014:fas Receptor / Q000235:genetics*
D000943:Antigens, Differentiation; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D048069:Tumor Necrosis Factors; D019014:fas Receptor